Market Overview:
Anti-viral Therapeutics Market size was valued US$ 51.72 billion in 2021 and is estimated to reach US$ 70.83 billion by 2029, growing at a CAGR of 4.6% during the forecast period (2022-2029).
Antiviral drugs are a category of medicine, which are utilized in treating viral infections, and maximum antivirals are used for precise viral infections. Antiviral capsules are sold prescription-primarily based simplest and are extraordinary from antibiotics, which fight towards bacterial infections. Unlike most antibiotics, antiviral remedy does now not smash the target pathogen,
however rather, they obstruct the improvement. Most antiviral drugs currently available are to help cope with herpes viruses, HIV, influenza A, and B viruses, and hepatitis B, and C viruses. Moreover, researchers are operating on expanding the range of antivirals to other households of pathogens.
To Download free sample @ Click Here
Market Dynamics
Increasing prevalence of viral infections and growing product launches are anticipated to pressure the market growth.
The international market for the antiviral therapeutics is in general pushed by means of the developing incidents of viral infections among populations. According to UNAIDS, in 2021, there were an estimated 38.4 million human beings [33.9 million–43.8 million] international living with HIV/AIDS, of which 28.7 million had been taking antiretroviral therapy, and an expected 1.Five million individuals have become newly inflamed with HIV. According to the World Health Organization (WHO) take a look at file 2022, an estimated 354 million humans are living with hepatitis B virus infection and in 2019, hepatitis B ended in 820 000 deaths. WHO estimated that 58 million human beings are infected with hepatitis C worldwide, of which 1.Five million new instances are recognized every yr.
Moreover, robust R&D, growing product launches for antiviral tablets coupled with the growing cognizance on viral infections and their remedies are of the important thing drivers in the antiviral therapeutics marketplace growth. For instance, in Mar 2022, ViiV Healthcare, HIV expert corporation owned with the aid of GSK, Pfizer and Shionogi introduced the approval of Cabenuva (cabotegravir, rilpivirine) for treating HIV-1 in teens which are virologically suppressed, at least 35 kg weight and elderly 12 years or older with strong antiretroviral regimen and no treatment failure history.
Strong pipelines are also going to power the increase of antiviral therapeutics marketplace. For instance, in May 2019, Atriva Therapeutics GmbH introduced the primary dose up of its lead drug candidate ATR-002 in a Phase I medical trial, marks the begin of the clinical improvement of a unique host-focused technique to treating influenza virus infections.
Market Segmentation:
By Mechanism of Action
- Nucleotide Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Application
- HIV
- Hepatitis
- Herpes Simplex Virus
- Influenza
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
Competitive Landscape
The key players in the global anti-viral therapeutics market include Roche, Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and Merck.
Companies are focusing on key strategies such as collaboration, acquisitions, and product launches which are boosting the growth of the market globally. For instance,
In Jul 2022, ViiV Healthcare, HIV specialist company oened by GSK and Pfizer announced its license agreement for cabotegravir long-acting related patents with Medicines Patent Pool to provide access in low income, least developed and Sub-Saharan African countries for pre-exposure prophylaxis of HIV.
Trending Topics:
Antimicrobial Therapeutics Market
Malignant Mesothelioma Therapeutics Market
Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/research-report/anti-viral-therapeutics-market